Daré Bioscience, Inc. (DARE)

Market Cap	28.82M
Revenue (ttm)	1.88M
Net Income (ttm)	-3.60M
Shares Out	8.70M
EPS (ttm)	-0.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	38,222
Open	3.290
Previous Close	3.300
Day's Range	3.280 - 3.450
52-Week Range	3.050 - 7.560
Beta	1.27
Analysts	Strong Buy
Price Target	20.33 (+513.79%)
Earnings Date	Nov 14, 2024

About DARE

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women’s health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female g...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Sabrina Johnson
• Employees: 26
• Stock Exchange: NASDAQ
• Ticker Symbol: DARE
• Website: https://darebioscience.com

Financial Performance

In 2023, Daré Bioscience's revenue was $2.81 million, a decrease of -71.92% compared to the previous year's $10.00 million. Losses were -$30.16 million, -2.54% less than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for DARE stock is "Strong Buy." The 12-month stock price forecast is $20.33, which is an increase of 513.79% from the latest price.

Price Target

$20.33

(513.79% upside)

Analyst Consensus: Strong Buy